Skip to main content
Finanzoo GmbH Finanzoo GmbH

Moderna, Inc Value Stock - Dividend - Research Selection

Moderna

ISIN: US60770K1079 , WKN: A2N9D9
Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!

How our site works ...

✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month 
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.


Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet

Description of the company

Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,

NEWS


What Moved Markets This Week

2026-07-25
Wall Street Breakfast recap: stocks slide on oil surge, tech earnings, tariffs and Middle East tensions.
SeekingAlpha

FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions

2026-07-25
The days ahead pack several binary or near-binary catalysts for U.S. biotech and biopharma companies—decisions that could sharply reshape valuations overnight.
Yahoo

Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know

2026-07-24
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo

Dassault Systemes SE (DASTF) (H1 2026) Earnings Call Highlights: Strong Subscription Growth and ...

2026-07-23
Despite challenges in life sciences and European automotive sectors, Dassault Systemes SE (DASTF) reports robust revenue growth and strategic advancements in AI and cloud solutions.
Yahoo

Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?

2026-07-23
With its first drug on the market and a pipeline full of catalysts, the company asks investors to weigh a powerful growth story against an elevated valuation and a history of volatility.
Yahoo

Earnings Preview: What To Expect From Moderna’s Report

2026-07-23
Moderna is likely to announce its fiscal second-quarter earnings by the end of this month, and analysts expect its losses to narrow.
Yahoo

Cheiron Raises $8M Seed Led by Menlo Ventures to Build the Operating System for Drug Programs

2026-07-22
Cheiron Founders Cheiron co-founders (from left): Harshit Gupta, co-founder and chief technology officer; Minseok Bae, co-founder and CEO; and Jason Park, co-founder and chief product officer. LOS ALTOS, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Cheiron, the operating system for drug programs, today announced an $8 million seed round led by Menlo Ventures, with the backing and strategic support of industry veterans including Moderna co-founder and MIT Institute Professor Robert Langer; former Pf
Yahoo

Fishbone Advisors Survey: Institutional Investors See Healthcare's AI Story as Overblown

2026-07-22
CHICAGO, July 22, 2026--Fishbone Advisors, a capital markets intelligence firm, today released a new report showing that healthcare's AI narrative has a credibility problem with institutional investors. In every healthcare subsector, roughly half to two-thirds of investors (48% to 67%) agree that management overemphasizes AI relative to its actual financial contribution, the most consistent finding in "Hallucinating Value: Healthcare's AI Narrative."
Yahoo

Is Moderna (MRNA) Fully Valued As Board Changes And Earnings Near?

2026-07-22
Moderna (MRNA) drew fresh attention after appointing experienced financial executive Michael McDonnell to its Board and Audit Committee, as the stock recently declined 3.77% and an earnings report is scheduled for July 31, 2026. See our latest analysis for Moderna. Moderna shares have been volatile, with the 7-day share price return down 11.54% and the 30-day share price return down 6.72%. However, the year to date share price return of 93.32% and 1-year total shareholder return of 82.28%...
Yahoo

Moderna (MRNA) Appoints Michael McDonnell To Board As Committee Roles Shift

2026-07-22
Moderna has appointed Michael McDonnell to its Board of Directors and Audit Committee. The company has adjusted certain Board committee memberships alongside his appointment. The changes bring additional financial and life sciences experience into Moderna’s governance structure. Moderna, traded on NasdaqGS:MRNA, is drawing attention for a fresh governance update rather than product news. The stock closed at $59.66, with returns up 93.3% year to date and up 82.3% over the past year, set...
Yahoo